Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iC9.GD2.CAR.IL-15 T-cells for Relapsed/Refractory Neuroblastoma or Osteosarcoma
NCT03721068Phase 1Recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Feb 2019
- Primary completion
- May 2030
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iC9-GD2.CAR.IL-15 T cells in neuroblastoma and osteosarcoma (OS), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Number of participants with adverse events at 4 weeks. Started Feb 2019; status: recruiting.
02
Drugs
iC9-GD2.CAR.IL-15 T cells
03
Conditions
neuroblastomaosteosarcoma (OS)
Beyond the preview
Go deeper on NCT03721068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03721068.